In participants with advanced renal-cell carcinoma, belzutifan, a HIF-2α inhibitor, was superior to everolimus, an mTOR inhibitor, with respect to progression-free survival and tumor response.
The New England Journal of Medicine: Search Results in Hematology/Oncology
